The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $111.11

Today's change0.00 0.00%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $111.11

Today's change0.00 0.00%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc closed at (U.S.)$111.11.

Over the last five days, shares have gained 3.35%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 43.07% during the last year.

Key company metrics

  • Open(U.S.) $108.67
  • Previous close(U.S.) $111.11
  • High(U.S.) $111.31
  • Low(U.S.) $106.05
  • Bid / Ask-- / --
  • YTD % change+2.26%
  • Volume360,795
  • Average volume (10-day)327,746
  • Average volume (1-month)326,926
  • Average volume (3-month)460,597
  • 52-week range(U.S.) $96.63 to (U.S.) $177.93
  • Beta-1.94
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$16.74
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,654.63%

Although this company's net profit margin is negative, it is above the industry average and implies that Intercept Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.63%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue14560
Total other revenue--------
Total revenue14560
Gross profit--------
Total cost of revenue--------
Total operating expense1288884128
Selling / general / administrative97444290
Research & development31444137
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-114-83-78-127
Interest income (expense), net non-operating-7-7----
Gain (loss) on sale of assets--------
Other--------
Income before tax-120-89-77-127
Income after tax-120-89-77-127
Income tax, total--------
Net income-120-89-77-127
Total adjustments to net income--------
Net income before extra. items-120-89-77-127
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-120-89-77-127
Inc. avail. to common incl. extra. items-120-89-77-127
Diluted net income-120-89-77-127
Dilution adjustment--------
Diluted weighted average shares25252524
Diluted EPS excluding extraordinary itemsvalue per share-4.84-3.59-3.14-5.17
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-4.84-3.59-3.14-5.17